Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03713515 · ClinicalTrials.gov registry record · Phase 4
Bridging the Evidence-to-practice Gap
A Phase 4 study of Hypertension, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 700
- Enrollment target
- 1
- Study location
NCT03713515 is a Phase 4 study of Hypertension that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 700 participants, below the 3,506-participant average among 470 other Hypertension trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03713515, a Phase 4 study of Hypertension, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 700 participants
- Enrollment target
- 1
- Study location
Study Summary
The proposed project will address this evidence-to-practice gap by evaluating the effect of practice facilitation (PF) of the intervention implementation fidelity (primary outcome) and clinical measures at 12 months (secondary outcomes).
Conditions Studied
Interventions
- BEHAVIORAL ALTA
Study Locations (1)
New York
- NYUMC Langone - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 700 participants |
| Start Date | 2020-12-01 |
| Est. Completion | 2027-11-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03713515
The ClinicalTrials.gov registry entry for NCT03713515 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 700 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,506-participant average among 470 other Hypertension trials with a reported enrollment target (80% lower). The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 1 intervention - of which ALTA is the first listed.
NCT03713515 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03713515 about?
NCT03713515 is a clinical study titled "Bridging the Evidence-to-practice Gap". The proposed project will address this evidence-to-practice gap by evaluating the effect of practice facilitation (PF) of the intervention implementation fidelity (primary outcome) and clinical measures at 12 months (secondary outcomes).
What is the current status of trial NCT03713515?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 700 participants. The study started on 2020-12-01. Estimated completion is 2027-11-30.
What conditions does trial NCT03713515 study?
This clinical trial studies the following conditions: Hypertension.
What interventions are being tested in trial NCT03713515?
The interventions under investigation include: ALTA (BEHAVIORAL).
Who is sponsoring clinical trial NCT03713515?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03713515 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment With Aspirin After Preeclampsia: TAP Trial
RECRUITING · Phase 4
-
Impact GLP-1 Agonists Following Bariatric
RECRUITING · Phase 4
-
Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study
RECRUITING · Phase 4
-
Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension
RECRUITING · Phase 4
-
Secondhand Tobacco Smoke and Cardiovascular Disease
RECRUITING · Phase 4
-
MR Antagonist and LSD1
ACTIVE NOT RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.